BLT benitec biopharma limited

Movement finally - website updated revealing the company may be...

  1. 2,820 Posts.
    lightbulb Created with Sketch. 618
    Movement finally - website updated revealing the company may be in the gutter but is looking up at stars.

    “”Benitec is a biotechnology company developing a proprietary therapeutic technology platform that combines RNA interference with gene therapy for the goal of providing sustained, long-lasting silencing of disease-causing genes from a single administration. We believe our technology has the potential to provide a “one shot” cure
    for a wide range of diseases that are currently addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options””.
    https://hotcopper.com.au/data/attachments/1720/1720890-a9b421972c2053dde00fd8f642530b1b.jpg
    “”At Benitec we are using this technology, called DNA-directed RNA interference , or ddRNAi, to develop a pipeline of product candidates in several chronic and life-threatening human disease areas including:Orphan disease: Oculopharyngeal Muscular Dystrophy (OPMD)Infectious disease: Hepatitis B Virus (HBV) In addition, we have licensed our ddRNAi technology to other biopharmaceutical companies whose pipeline programs are progressing towards, the clinic or are in, clinical development for applications including HIV/AIDS, retinitis pigmentosa, Huntington’s disease, cancer immunotherapy and intractable neuropathic pain.””

    Note the position of the orange arrow for the OPMD program. Two times in recent weeks we see the same arrow showing OPMD as virtually clinic ready.














    Last edited by lawrence1967: 10/09/19
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.